Ovid Therapeutics (OVID) Competitors

Ovid Therapeutics logo
$2.40 -0.14 (-5.51%)
Closing price 04:00 PM Eastern
Extended Trading
$2.42 +0.02 (+0.63%)
As of 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

OVID vs. TRVI, PBH, TRLV, HRMY, and ETON

Should you buy Ovid Therapeutics stock or one of its competitors? Ovid Therapeutics's main competitors and comparable companies include Trevi Therapeutics (TRVI), Prestige Consumer Healthcare (PBH), Trulieve Cannabis (TRLV), Harmony Biosciences (HRMY), and Eton Pharmaceuticals (ETON). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Ovid Therapeutics compare to Trevi Therapeutics?

Trevi Therapeutics (NASDAQ:TRVI) and Ovid Therapeutics (NASDAQ:OVID) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, institutional ownership, media sentiment, earnings, dividends, analyst recommendations, valuation and profitability.

In the previous week, Trevi Therapeutics had 11 more articles in the media than Ovid Therapeutics. MarketBeat recorded 22 mentions for Trevi Therapeutics and 11 mentions for Ovid Therapeutics. Trevi Therapeutics' average media sentiment score of 0.19 beat Ovid Therapeutics' score of -0.14 indicating that Trevi Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Trevi Therapeutics
4 Very Positive mention(s)
1 Positive mention(s)
8 Neutral mention(s)
3 Negative mention(s)
0 Very Negative mention(s)
Neutral
Ovid Therapeutics
1 Very Positive mention(s)
2 Positive mention(s)
2 Neutral mention(s)
3 Negative mention(s)
1 Very Negative mention(s)
Neutral

Ovid Therapeutics has higher revenue and earnings than Trevi Therapeutics. Trevi Therapeutics is trading at a lower price-to-earnings ratio than Ovid Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Trevi TherapeuticsN/AN/A-$42.76M-$0.39N/A
Ovid Therapeutics$7.25M66.12-$17.41M-$0.24N/A

Trevi Therapeutics has a beta of 1.15, suggesting that its share price is 15% more volatile than the broader market. Comparatively, Ovid Therapeutics has a beta of 0.24, suggesting that its share price is 76% less volatile than the broader market.

95.8% of Trevi Therapeutics shares are held by institutional investors. Comparatively, 72.2% of Ovid Therapeutics shares are held by institutional investors. 15.4% of Trevi Therapeutics shares are held by insiders. Comparatively, 7.0% of Ovid Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Ovid Therapeutics' return on equity of -23.38% beat Trevi Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Trevi TherapeuticsN/A -24.81% -23.96%
Ovid Therapeutics N/A -23.38%-20.76%

Trevi Therapeutics currently has a consensus price target of $27.08, suggesting a potential upside of 98.41%. Ovid Therapeutics has a consensus price target of $6.00, suggesting a potential upside of 136.22%. Given Ovid Therapeutics' higher probable upside, analysts plainly believe Ovid Therapeutics is more favorable than Trevi Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Trevi Therapeutics
1 Sell rating(s)
0 Hold rating(s)
11 Buy rating(s)
1 Strong Buy rating(s)
2.92
Ovid Therapeutics
1 Sell rating(s)
0 Hold rating(s)
11 Buy rating(s)
1 Strong Buy rating(s)
2.92

Summary

Ovid Therapeutics beats Trevi Therapeutics on 7 of the 12 factors compared between the two stocks.

How does Ovid Therapeutics compare to Prestige Consumer Healthcare?

Prestige Consumer Healthcare (NYSE:PBH) and Ovid Therapeutics (NASDAQ:OVID) are both healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, institutional ownership, valuation, profitability, media sentiment, analyst recommendations, earnings and dividends.

Prestige Consumer Healthcare presently has a consensus price target of $67.00, suggesting a potential upside of 45.48%. Ovid Therapeutics has a consensus price target of $6.00, suggesting a potential upside of 136.22%. Given Ovid Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Ovid Therapeutics is more favorable than Prestige Consumer Healthcare.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Prestige Consumer Healthcare
1 Sell rating(s)
3 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00
Ovid Therapeutics
1 Sell rating(s)
0 Hold rating(s)
11 Buy rating(s)
1 Strong Buy rating(s)
2.92

Prestige Consumer Healthcare has a beta of 0.3, indicating that its stock price is 70% less volatile than the broader market. Comparatively, Ovid Therapeutics has a beta of 0.24, indicating that its stock price is 76% less volatile than the broader market.

Prestige Consumer Healthcare has higher revenue and earnings than Ovid Therapeutics. Ovid Therapeutics is trading at a lower price-to-earnings ratio than Prestige Consumer Healthcare, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Prestige Consumer Healthcare$1.09B2.01$190.30M$3.2414.21
Ovid Therapeutics$7.25M66.12-$17.41M-$0.24N/A

Prestige Consumer Healthcare has a net margin of 13.29% compared to Ovid Therapeutics' net margin of 0.00%. Prestige Consumer Healthcare's return on equity of 11.28% beat Ovid Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Prestige Consumer Healthcare13.29% 11.28% 5.25%
Ovid Therapeutics N/A -23.38%-20.76%

100.0% of Prestige Consumer Healthcare shares are owned by institutional investors. Comparatively, 72.2% of Ovid Therapeutics shares are owned by institutional investors. 1.5% of Prestige Consumer Healthcare shares are owned by insiders. Comparatively, 7.0% of Ovid Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

In the previous week, Ovid Therapeutics had 9 more articles in the media than Prestige Consumer Healthcare. MarketBeat recorded 11 mentions for Ovid Therapeutics and 2 mentions for Prestige Consumer Healthcare. Ovid Therapeutics' average media sentiment score of -0.14 beat Prestige Consumer Healthcare's score of -0.18 indicating that Ovid Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Prestige Consumer Healthcare
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Ovid Therapeutics
1 Very Positive mention(s)
2 Positive mention(s)
2 Neutral mention(s)
3 Negative mention(s)
1 Very Negative mention(s)
Neutral

Summary

Prestige Consumer Healthcare beats Ovid Therapeutics on 9 of the 17 factors compared between the two stocks.

How does Ovid Therapeutics compare to Trulieve Cannabis?

Trulieve Cannabis (NYSE:TRLV) and Ovid Therapeutics (NASDAQ:OVID) are related small-cap companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, profitability, analyst recommendations, dividends, valuation, earnings, media sentiment and risk.

In the previous week, Ovid Therapeutics had 5 more articles in the media than Trulieve Cannabis. MarketBeat recorded 11 mentions for Ovid Therapeutics and 6 mentions for Trulieve Cannabis. Trulieve Cannabis' average media sentiment score of 0.47 beat Ovid Therapeutics' score of -0.14 indicating that Trulieve Cannabis is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Trulieve Cannabis
1 Very Positive mention(s)
2 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Ovid Therapeutics
1 Very Positive mention(s)
2 Positive mention(s)
2 Neutral mention(s)
3 Negative mention(s)
1 Very Negative mention(s)
Neutral

72.2% of Ovid Therapeutics shares are owned by institutional investors. 3.8% of Trulieve Cannabis shares are owned by company insiders. Comparatively, 7.0% of Ovid Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Trulieve Cannabis presently has a consensus target price of $15.00, suggesting a potential upside of 38.44%. Ovid Therapeutics has a consensus target price of $6.00, suggesting a potential upside of 136.22%. Given Ovid Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Ovid Therapeutics is more favorable than Trulieve Cannabis.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Trulieve Cannabis
1 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00
Ovid Therapeutics
1 Sell rating(s)
0 Hold rating(s)
11 Buy rating(s)
1 Strong Buy rating(s)
2.92

Ovid Therapeutics has lower revenue, but higher earnings than Trulieve Cannabis. Ovid Therapeutics is trading at a lower price-to-earnings ratio than Trulieve Cannabis, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Trulieve Cannabis$1.18B1.57-$116.38M$0.2054.18
Ovid Therapeutics$7.25M66.12-$17.41M-$0.24N/A

Ovid Therapeutics has a net margin of 0.00% compared to Trulieve Cannabis' net margin of -41.22%. Trulieve Cannabis' return on equity of -0.34% beat Ovid Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Trulieve Cannabis-41.22% -0.34% -0.14%
Ovid Therapeutics N/A -23.38%-20.76%

Summary

Ovid Therapeutics beats Trulieve Cannabis on 10 of the 16 factors compared between the two stocks.

How does Ovid Therapeutics compare to Harmony Biosciences?

Harmony Biosciences (NASDAQ:HRMY) and Ovid Therapeutics (NASDAQ:OVID) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, dividends, earnings, media sentiment, risk, institutional ownership, profitability and analyst recommendations.

Harmony Biosciences has a beta of 1, suggesting that its stock price has a similar volatility profile to the broader market.Comparatively, Ovid Therapeutics has a beta of 0.24, suggesting that its stock price is 76% less volatile than the broader market.

Harmony Biosciences has higher revenue and earnings than Ovid Therapeutics. Ovid Therapeutics is trading at a lower price-to-earnings ratio than Harmony Biosciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Harmony Biosciences$989.36M2.00$158.69M$3.0211.18
Ovid Therapeutics$7.25M66.12-$17.41M-$0.24N/A

Harmony Biosciences has a net margin of 18.05% compared to Ovid Therapeutics' net margin of 0.00%. Harmony Biosciences' return on equity of 18.55% beat Ovid Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Harmony Biosciences18.05% 18.55% 13.24%
Ovid Therapeutics N/A -23.38%-20.76%

In the previous week, Harmony Biosciences had 6 more articles in the media than Ovid Therapeutics. MarketBeat recorded 17 mentions for Harmony Biosciences and 11 mentions for Ovid Therapeutics. Harmony Biosciences' average media sentiment score of 0.38 beat Ovid Therapeutics' score of -0.14 indicating that Harmony Biosciences is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Harmony Biosciences
4 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
1 Very Negative mention(s)
Neutral
Ovid Therapeutics
1 Very Positive mention(s)
2 Positive mention(s)
2 Neutral mention(s)
3 Negative mention(s)
1 Very Negative mention(s)
Neutral

86.2% of Harmony Biosciences shares are owned by institutional investors. Comparatively, 72.2% of Ovid Therapeutics shares are owned by institutional investors. 11.0% of Harmony Biosciences shares are owned by insiders. Comparatively, 7.0% of Ovid Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Harmony Biosciences currently has a consensus price target of $48.00, indicating a potential upside of 42.18%. Ovid Therapeutics has a consensus price target of $6.00, indicating a potential upside of 136.22%. Given Ovid Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Ovid Therapeutics is more favorable than Harmony Biosciences.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Harmony Biosciences
1 Sell rating(s)
5 Hold rating(s)
6 Buy rating(s)
1 Strong Buy rating(s)
2.54
Ovid Therapeutics
1 Sell rating(s)
0 Hold rating(s)
11 Buy rating(s)
1 Strong Buy rating(s)
2.92

Summary

Harmony Biosciences beats Ovid Therapeutics on 12 of the 16 factors compared between the two stocks.

How does Ovid Therapeutics compare to Eton Pharmaceuticals?

Eton Pharmaceuticals (NASDAQ:ETON) and Ovid Therapeutics (NASDAQ:OVID) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, risk, earnings, analyst recommendations, institutional ownership, profitability, valuation and dividends.

27.9% of Eton Pharmaceuticals shares are owned by institutional investors. Comparatively, 72.2% of Ovid Therapeutics shares are owned by institutional investors. 16.5% of Eton Pharmaceuticals shares are owned by company insiders. Comparatively, 7.0% of Ovid Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Eton Pharmaceuticals has higher revenue and earnings than Ovid Therapeutics. Ovid Therapeutics is trading at a lower price-to-earnings ratio than Eton Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Eton Pharmaceuticals$79.95M23.06-$4.60M$1.5142.34
Ovid Therapeutics$7.25M66.12-$17.41M-$0.24N/A

Eton Pharmaceuticals has a beta of 0.89, meaning that its stock price is 11% less volatile than the broader market. Comparatively, Ovid Therapeutics has a beta of 0.24, meaning that its stock price is 76% less volatile than the broader market.

Eton Pharmaceuticals has a net margin of 35.35% compared to Ovid Therapeutics' net margin of 0.00%. Eton Pharmaceuticals' return on equity of 104.82% beat Ovid Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Eton Pharmaceuticals35.35% 104.82% 43.09%
Ovid Therapeutics N/A -23.38%-20.76%

In the previous week, Eton Pharmaceuticals had 5 more articles in the media than Ovid Therapeutics. MarketBeat recorded 16 mentions for Eton Pharmaceuticals and 11 mentions for Ovid Therapeutics. Eton Pharmaceuticals' average media sentiment score of 0.47 beat Ovid Therapeutics' score of -0.14 indicating that Eton Pharmaceuticals is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Eton Pharmaceuticals
5 Very Positive mention(s)
4 Positive mention(s)
2 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral
Ovid Therapeutics
1 Very Positive mention(s)
2 Positive mention(s)
2 Neutral mention(s)
3 Negative mention(s)
1 Very Negative mention(s)
Neutral

Eton Pharmaceuticals presently has a consensus target price of $79.75, suggesting a potential upside of 24.75%. Ovid Therapeutics has a consensus target price of $6.00, suggesting a potential upside of 136.22%. Given Ovid Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Ovid Therapeutics is more favorable than Eton Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Eton Pharmaceuticals
0 Sell rating(s)
1 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.83
Ovid Therapeutics
1 Sell rating(s)
0 Hold rating(s)
11 Buy rating(s)
1 Strong Buy rating(s)
2.92

Summary

Eton Pharmaceuticals beats Ovid Therapeutics on 11 of the 17 factors compared between the two stocks.

Get Ovid Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for OVID and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding OVID and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

OVID vs. The Competition

MetricOvid TherapeuticsPharmaceuticals IndustryHealthcare SectorNASDAQ Exchange
Market Cap$481.27M$13.75B$7.85B$12.17B
Dividend YieldN/A2.58%2.46%4.41%
P/E RatioN/A26.0432.9127.37
Price / Sales62.487.318.595.73
Price / CashN/A15.7421.9322.50
Price / Book2.295.144.403.70
Net Income-$17.41M$2.88B$3.52B$392.17M
7 Day Performance-15.79%-3.87%-5.34%-4.53%
1 Month Performance11.63%-3.96%-3.61%-5.86%
1 Year Performance83.91%-7.13%0.01%-7.78%

Ovid Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
OVID
Ovid Therapeutics
2.45 of 5 stars
$2.40
-5.5%
$6.00
+150.0%
+94.6%$481.27M$7.25MN/A23
TRVI
Trevi Therapeutics
2.1792 of 5 stars
$14.70
-4.0%
$27.08
+84.3%
+20.1%$2.09BN/AN/A34
PBH
Prestige Consumer Healthcare
2.8254 of 5 stars
$44.12
+1.0%
$67.00
+51.9%
-23.2%$2.09B$1.09B13.62890
TRLV
Trulieve Cannabis
3.64 of 5 stars
$10.84
-1.6%
$15.00
+38.4%
N/A$2.09B$1.18B98.505,000
HRMY
Harmony Biosciences
4.4152 of 5 stars
$33.58
-0.6%
$48.00
+43.0%
-0.8%$1.96B$868.45M11.12293

Related Companies and Tools


This page (NASDAQ:OVID) was last updated on 11/16/2026 by MarketBeat.com Staff.
From Our Partners